Clinic
Premier Pain Treatment Institute, LLC
Premier Pain Treatment Institute, LLC was paid $4.13M by Medicaid between Jan 2018 and Dec 2024, across 38 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 41% of everything it billed.
33Billing provider infoPREMIER PAIN TREATMENT INSTITUTE, LLC
LOVELAND, OH 45140
LOVELAND, OH 45140
33aNPI1083079941assigned 12/19/2015
33bProvider typePain Clinic/Center
28Total paid$4.13M
24GClaims131,586
24DCodes billed38
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Pain Clinic/Center providers in Ohio
Rank by total paid#2 of 8
Median peer was paid$239K
This provider vs. median17×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,870 | $485K | |
| 2019 | 18,789 | $656K | |
| 2020 | 15,654 | $562K | |
| 2021 | 16,006 | $616K | |
| 2022 | 17,729 | $597K | |
| 2023 | 15,854 | $561K | |
| 2024incomplete | 21,684 | $654K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 41% | 40,004 | 37,555 | $1.69M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 27% | 41,665 | 38,722 | $1.13M |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 21% | 27,489 | 26,068 | $852K |
| 99204 | Doctor's office visit, new patient (more involved)Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity | 3.5% | 2,316 | 2,221 | $146K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 1.9% | 1,127 | 1,085 | $80K |
| 76942 | <1% | 1,341 | 1,263 | $38K | |
| 64493 | <1% | 561 | 517 | $35K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 725 | 701 | $31K |
| 62370 | <1% | 1,105 | 1,053 | $27K | |
| 20611 | <1% | 368 | 337 | $18K | |
| 64494 | <1% | 608 | 486 | $17K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 124 | 116 | $17K |
26 more codes
| 64483 | <1% | 210 | $13K | |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 133 | $12K |
| 96127 | <1% | 2,460 | $5K | |
| 64635 | <1% | 55 | $5K | |
| 62368 | <1% | 164 | $3K | |
| 27096 | <1% | 36 | $2K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 3,252 | $2K |
| 64636 | <1% | 42 | $2K | |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | <1% | 109 | $1K |
| 62323 | <1% | 15 | $1K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 62 | $662.09 |
| 36415 | Collection of venous blood by venipuncture | <1% | 247 | $137.15 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 145 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 2,017 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 156 | $0.00 |
| G8404 | Lower extremity neurological exam performed and documented | 0% | 459 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 2,018 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 160 | $0.00 |
| G9368 | At least two orders for high-risk medications from the same drug class not ordered | 0% | 206 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 149 | $0.00 |
| 4004F | 0% | 606 | $0.00 | |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 159 | $0.00 |
| G9366 | One high-risk medication not ordered | 0% | 203 | $0.00 |
| 1036F | 0% | 688 | $0.00 | |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 146 | $0.00 |
| 1006F | 0% | 256 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialDANKO, MICHAEL (OWNER)